REG - Immupharma PLC - Exercise of Warrants

ImmuPharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250917:nRSQ5736Za&default-theme=true

RNS Number : 5736Z  Immupharma PLC  17 September 2025

 
17 September 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

Exercise of Options

 

ImmuPharma plc (LSE : IMM), the specialist drug discovery and development
company, announces that the Company has received notice of exercise of
500,000 warrants over New Ordinary Shares of 1p each ("Ordinary Shares") at an
exercise price of 5p per share, for a consideration of £25,000.

 

New Ordinary Shares and Admission

 

The New Ordinary Shares have been allotted today and are issued credited as
fully paid and will rank pari passu in all respects with the Company's
existing issued ordinary shares.

 

An application will be made for the New Ordinary Shares to be admitted to
trading on the AIM market ("Admission") of the London Stock Exchange. It is
anticipated that Admission will occur on or around Monday 22 September
2025.

 

The New Ordinary Shares represent 0.10% of the Company's enlarged issued share
capital.

 

Total Shares in Issue

 

For the purposes of the Disclosure Guidance and Transparency Rules of the
Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies
the market that following Admission, the Company's total issued share capital
will consist of 502,723,932 Ordinary Shares with a nominal value of 1p each.

This figure may be used by Shareholders as the denominator for the
calculations by which they may determine if they are required to notify their
interest in, or a change to their interest in, the Company under the DTR.

 

Ends

This announcement contains inside information as stipulated under the UK
version of the Market Abuse Regulation no 596/2014 which is part of English
law by virtue of the European (withdrawal) Act 2018, as amended.  On
publication of this announcement via a regulatory information service, this
information is considered to be in the public domain.

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.co.uk (http://www.immupharma.co.uk) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer

 Lisa Baderoon, Head of Investor Relations                             + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                               +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                              +44 (0) 20 3650 3650

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                             +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk) .

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEFLFESAVIRLIE